AMENDMENT #1 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 5th, 2020 • Assembly Biosciences, Inc. • Pharmaceutical preparations
This Amendment #1 to Exclusive License Agreement (“Amendment #1”) is entered into as of February 28, 2017 (the “Amendment #1 Effective Date”) by and between The Indiana University Research and Technology Corporation, a non-profit corporation organized under the laws of the state of Indiana, having its principal offices at 518 Indiana Ave, Indianapolis, IN 46202 (“IURTC”) and Assembly Biosciences, Inc. (the parent company and assignee of Assembly Pharmaceuticals, Inc.), a company organized under the laws of the state of Delaware, having its principal offices at 11711 N. Meridian Street, Suite 310, Carmel, Indiana, 46032 (“Assembly”) and acknowledged by Assembly Pharmaceuticals, Inc., a Delaware corporation and wholly owned subsidiary of Assembly (“AP”). IURTC and Assembly may each be referred to herein as a “Party” and collectively as the “Parties”.
AMENDMENT #2 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 5th, 2020 • Assembly Biosciences, Inc. • Pharmaceutical preparations
This Amendment #2 to Exclusive License Agreement (this “Amendment #2”) is entered into and effective as of July 10, 2020 (the “Amendment #2 Effective Date”) by and between Indiana University Research and Technology Corporation, a non-profit corporation organized under the laws of the state of Indiana, having its principal offices at 518 Indiana Ave., Indianapolis, Indiana 46202 (“IURTC”) and Assembly Biosciences, Inc. (the parent company and assignee of Assembly Pharmaceuticals, Inc.), a Delaware corporation, having its principal offices at 331 Oyster Point Blvd., Fourth Floor, South San Francisco, California 94080 (“Assembly”). IURTC and Assembly may each be referred to herein as a “Party” and collectively as the “Parties”.
COLLABORATION AGREEMENTCollaboration Agreement • November 5th, 2020 • Assembly Biosciences, Inc. • Pharmaceutical preparations • New York
This Collaboration Agreement (this “Agreement”) is made as of July 17, 2020 (the “Effective Date”), by and between Assembly Biosciences, Inc., a corporation organized and existing under the laws of Delaware (“AssemblyBio”), having a place of business at 331 Oyster Point Blvd., 4th Floor, South San Francisco, CA 94080, and BeiGene, Ltd., a Cayman Island exempted company incorporated with limited liability (“BeiGene”), having a place of business at c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, PO Box 1348, Grand Cayman KY1-1108, Cayman Islands. AssemblyBio and BeiGene are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
